Nykredit A/S’s Neurocrine Biosciences NBIX Stock Holding History

Nykredit A/S’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$6.3M	Buy	+37,372	New	+$5.54M	0.02%	475

Other funds holding NBIX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Nykredit A/S's NBIX Position: Q2 2026 in Review

Nykredit A/S opened a new position in Neurocrine Biosciences (NBIX) in Q2 2026: 37,372 shares worth $6.3M. The stake represents 0.02% of the portfolio and ranks #475 among its holdings.

620 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

Nykredit A/S held 37,372 shares of Neurocrine Biosciences worth $6.3M as of Q2 2026.
Neurocrine Biosciences was a new Nykredit A/S position in Q2 2026.
Neurocrine Biosciences made up 0.02% of Nykredit A/S's portfolio in Q2 2026, its #475 holding.
620 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Nykredit A/S's 13F filing for Q2 2026, filed 13 Aug 2026.